about female fertility
Infertility is a common reproductive system disorder that affects millions of couples globally, significantly impacting both families and their communities. According to research, approximately one in every six individuals of reproductive age around the world experience infertility at some point in their lives.²
IVF (In Vitro Fertilization) can present significant challenges, including the substantial financial burden, the need for time off work for various procedures, and the emotional strain on both the individual undergoing treatment and her loved ones. Additionally, there are health risks associated with IVF, such as potential side effects from medications and an increased likelihood of multiple pregnancies, which carry their own risks, including premature birth and low birth weight.
how is Heranova
addressing female fertility?
Heranova™ is currently building a suite of four state-of-the-art tests to provide women with more information and more choices regarding their fertility. These tests are now in the clinical stage:
HerReceptivity™, HerBiota™, HerBiota™—Complete and HerTempo™.
Read more about female infertility
symptoms and causes
Learn about the unmet needs
presented by female infertility
female infertility symptoms & causes
Infertility is defined as the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.7
In the female reproductive system, infertility may be caused by:
- Tubal disorders such as blocked fallopian tubes, which are in turn caused by untreated sexually transmitted infections (STIs) or complications of unsafe abortion, postpartum sepsis, or abdominal/pelvic surgery
- Uterine disorders which could be inflammatory (such as endometriosis), congenital (such as septate uterus), or benign (such as fibroids)
- Disorders of the ovaries, such as polycystic ovarian syndrome and other follicular disorders
- Disorders of the endocrine system which can lead to imbalances in reproductive hormones. The hypothalamus and pituitary glands are part of the endocrine system, and common disorders affecting this system include hypopituitarism and pituitary cancers.
unmet needs presented
by female infertility
While assisted reproduction technologies (ART) have been available for more than three decades, with more than 5 million children born worldwide from ART interventions such as in vitro fertilization (IVF)13, the overall success rates are still far from satisfactory.
how is HerAnova
addressing female fertility?
HerAnova™ is currently building a suite of four state-of-the-art tests to provide women with more information and more choices regarding their fertility. These tests are now in the clinical stage:
HerEndo™, HerBiota™ and HerTempo™.
indication
PRODUCT
DESCRIPTION
pre-clinical
clinical
launched
Female fertility
HerReceptivityTM
HerReceptivity™ is an NGS-based test to identify each patient’s optimal embryo transplantation time during the IVF process. The average success rate of IVF procedures is currently only ~50% for women under 35 using their own eggs5, and 10% of patients experience recurrent implantation failure caused by repeated IVF failure.6
Endometrial receptivity test
HerBiotaTM
Uterine microbiome test
HerBiotaTM - Complete
Uterine/vaginal microbiome test
HerTempoTM
HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.
Ovarian reserve test
Endometriosis
HerResolveTM
Diagnostic test for endometriosis
Launched
First-in-class blood-based diagnostic test. Endometriosis is a highly debilitating disease impacting 10% of reproductive-age women, but the current gold standard for confirming diagnosis is laparoscopic surgery, which can often result in mis- or late diagnosis.4
Female fertility
HerEndoTM
Microbiome-based endometriosis screening
Clinical
HerEndo™ is a minimally invasive, vaginal swab test designed to provide a comprehensive assessment of the vaginal microbiome, including bacterial and fungal composition and associated antibiotic resistance markers in patients with symptoms suggestive of endometriosis. By leveraging qPCR and next-generation sequencing, HerEndo amplifies and analyzes a universal microbial gene target, enabling broad, species-level detection beyond the limitations of traditional targeted approaches. Imbalances in the vaginal microbiome may be associated with early-stage endometriosis, and patients identified through HerEndo can reflex to HerResolve™, a blood-based test, to help confirm the presence of disease and support more informed clinical decision-making.
HerBiotaTM
Uterine microbiome test
Clinical
HerTempoTM
Ovarian reserve test
Clinical
HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.